Sara Guariglia,  —

Planned Study Aims for Way to Personalize Multiple Myeloma Treatment

A nonprofit–industry partnership, led by RCSI University of Medicine and Health Sciences of Dublin and SkylineDx, aims to advance genetic testing to better guide doctors in making treatment choices for people with multiple myeloma, based on each patient’s likely response. A planned study in patients, conducted with funding from…

ONCOTracker, Binding Site Team Up to Develop sBCMA Monitoring Test

ONCOTracker and The Binding Site have entered an agreement to develop and commercialize a new test that measures serum levels of the B-cell maturation antigen (sBCMA) protein to monitor people with blood cancers, including multiple myeloma. Under the agreement, The Binding Site has gained exclusive rights…